Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 191

1.

Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab.

Wadlow RC, Hezel AF, Abrams TA, Blaszkowsky LS, Fuchs CS, Kulke MH, Kwak EL, Meyerhardt JA, Ryan DP, Szymonifka J, Wolpin BM, Zhu AX, Clark JW.

Oncologist. 2012;17(1):14. doi: 10.1634/theoncologist.2011-0452. Epub 2011 Dec 30.

2.

Panitumumab after progression on cetuximab in KRAS wild-type metastatic colorectal cancer patients: a single institution experience.

Marino A, Caliolo C, Sponziello F, Nacci A, Quaranta A, Mazzoni E, Lutrino SE, Rizzo P, Calvani N, Orlando L, Schiavone P, Fedele P, D'Amico M, Chetrì MC, Cinefra M, Ferrara P, Cinieri S.

Tumori. 2015 Sep-Oct;101(5):524-8. doi: 10.5301/tj.5000356. Epub 2015 May 25.

PMID:
26045117
3.

Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.

Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, Thomas A, Tjulandin S, Zhang K, Murugappan S, Sidhu R.

Lancet Oncol. 2014 May;15(6):569-79. doi: 10.1016/S1470-2045(14)70118-4. Epub 2014 Apr 14.

PMID:
24739896
4.

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.

Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, Gwyther S, Lowe C, Seligmann JF, Wadsley J, Maisey N, Chau I, Hill M, Dawson L, Falk S, O'Callaghan A, Benstead K, Chambers P, Oliver A, Marshall H, Napp V, Quirke P.

Lancet Oncol. 2013 Jul;14(8):749-59. doi: 10.1016/S1470-2045(13)70163-3. Epub 2013 May 29.

5.

Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer.

Reidy DL, Vakiani E, Fakih MG, Saif MW, Hecht JR, Goodman-Davis N, Hollywood E, Shia J, Schwartz J, Chandrawansa K, Dontabhaktuni A, Youssoufian H, Solit DB, Saltz LB.

J Clin Oncol. 2010 Sep 20;28(27):4240-6. doi: 10.1200/JCO.2010.30.4154. Epub 2010 Aug 16.

6.

Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacy.

Pietrantonio F, Perrone F, Biondani P, Maggi C, Lampis A, Bertan C, Venturini F, Tondulli L, Ferrari D, Ricci V, Villa F, Barone G, Bianco N, Ghidini A, Bossi I, Fanetti G, Di Bartolomeo M, de Braud F.

Cancer Biol Ther. 2013 Dec;14(12):1098-103. doi: 10.4161/cbt.26343. Epub 2013 Sep 4.

7.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A.

J Clin Oncol. 2008 Dec 10;26(35):5705-12. doi: 10.1200/JCO.2008.18.0786. Epub 2008 Nov 10.

8.

Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.

Kang MJ, Hong YS, Kim KP, Kim SY, Baek JY, Ryu MH, Lee JL, Chang HM, Kim MJ, Chang HJ, Kang YK, Kim TW.

Invest New Drugs. 2012 Aug;30(4):1607-13. doi: 10.1007/s10637-011-9703-8. Epub 2011 Jun 25.

PMID:
21706149
10.

Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions.

Saif MW, Kaley K, Chu E, Copur MS.

Clin Colorectal Cancer. 2010 Dec;9(5):315-8. doi: 10.3816/CCC.2010.n.046.

PMID:
21208847
11.

Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.

Tol J, Punt CJ.

Clin Ther. 2010 Mar;32(3):437-53. doi: 10.1016/j.clinthera.2010.03.012. Review.

PMID:
20399983
12.

Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.

Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA.

Ann Intern Med. 2011 Jan 4;154(1):37-49. doi: 10.7326/0003-4819-154-1-201101040-00006. Review.

PMID:
21200037
13.

KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2010;10(25):1-49. Epub 2010 Dec 1.

14.

No survival benefit from adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer in KRAS wild type patients: a meta-analysis.

Zhou SW, Huang YY, Wei Y, Jiang ZM, Zhang YD, Yang Q, Xie DR.

PLoS One. 2012;7(11):e50925. doi: 10.1371/journal.pone.0050925. Epub 2012 Nov 30.

15.

Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.

László L.

Magy Onkol. 2010 Dec;54(4):383-94. doi: 10.1556/MOnkol.54.2010.4.13.

16.

Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer.

Hoyle M, Peters J, Crathorne L, Jones-Hughes T, Cooper C, Napier M, Hyde C.

Value Health. 2013 Mar-Apr;16(2):288-96. doi: 10.1016/j.jval.2012.11.001. Epub 2013 Jan 23.

17.

Panitumumab: in metastatic colorectal cancer with wild-type KRAS.

Weber J, McCormack PL.

BioDrugs. 2008;22(6):403-11. doi: 10.2165/0063030-200822060-00006. Review.

PMID:
18998757
18.

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD.

J Clin Oncol. 2008 Apr 1;26(10):1626-34. doi: 10.1200/JCO.2007.14.7116. Epub 2008 Mar 3.

19.

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J.

J Clin Oncol. 2010 Nov 1;28(31):4697-705. doi: 10.1200/JCO.2009.27.4860. Epub 2010 Oct 4.

PMID:
20921465
20.

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S.

JAMA. 2010 Oct 27;304(16):1812-20. doi: 10.1001/jama.2010.1535.

PMID:
20978259

Supplemental Content

Support Center